INTRODUCTION {#S1}
============

Allogeneic hematopoietic cell transplants (HCT) has been shown to be a valuable and potentially curative strategy to treat patients with high-risk lymphoma.^[@R1]-[@R6]^ Reduced-intensity conditioning (RIC) regimens have further expanded the use of allogeneic HCT to those who relapse after autologous HCT, older patients and persons with significant pre-transplant co-morbidities.^[@R6]-[@R10]^

Donor availability is a potential barrier for patients who are candidates for allogeneic HCT, but lack an adequately human leukocyte antigen (HLA)-matched and clinically suitable sibling donor. While Caucasian patients have a 60-70% probability of identifying an 8/8 allele level HLA-matched unrelated donor (MUD), for ethnic minority groups fewer than 30% find a well-matched donor.^[@R11]^ In the past 10 years, a growing number of reports supported an expanding utilization of HLA-mismatched unrelated donors (MMUD), umbilical cord blood (UCB) and partially HLA-matched family donors (haploidentical) as valuable alternatives to fill the gap in donor availability.^[@R12]-[@R14]^

However, data on the relative efficacy of alternative donor HCT for adults with high-risk lymphoma are limited and there are no data on comparison of 7/8 versus 8/8 HLA-matched unrelated donors and UCB.^[@R7],[@R9],[@R15]-[@R20]^ Thus, we performed a retrospective registry based analysis studying the outcomes of patients with advanced lymphoma who received an allograft from MUD, MMUD or UCB using data from the Center for International Blood and Marrow Transplant Research (CIBMTR).

PATIENTS AND METHODS {#S2}
====================

Data source {#S3}
-----------

The CIBMTR, a voluntary working group of more than 450 transplantation centers worldwide, collects data on consecutive allogeneic HCTs at a statistical center housed at both the Medical College of Wisconsin (Milwaukee, WI) and the National Marrow Donor Program (Minneapolis, MN). Patients are observed longitudinally with yearly follow-up. Computerized checks for errors and onsite audits of participating centers ensure data quality. The present study was conducted with a waiver of informed consent and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the Institutional Board and the Privacy Officer of the Medical College of Wisconsin.

Study Population {#S4}
----------------

In this comparative study, we included patients ≥ 18 years-old with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) who underwent transplant with an 8/8 allele HLA-matched donor (MUD), 1 antigen or allele MMUD and UCB transplanted in the United States between 2000-2010. We verified HLA matching for all cases included in this study. Forty-nine percent were retrospectively typed using stored samples for NMDP/CIBMTR research repository;^[@R21]^ 43% were NMDP facilitated transplants and 9% had HLA typing reported by the transplant center. A contemporary haploidentical related donor cohort had only 39 patients with a short median follow-up of 14 months and was excluded from this analysis. Patients with planned second transplants, ex-vivo manipulated grafts and those with rare aggressive histologies (ie, aggressive NK cell neoplasms, lymphoblastic lymphoma, Burkitt lymphoma, primary central nervous system lymphoma) were excluded. Preparative regimens were classified either as RIC or myeloablative conditioning (MAC) according to published consensus definitions.^[@R22]^ RIC regimens included melphalan ≤ 140 mg/m2, busulfan ≤ 9 mg/kg orally, total body irradiation \<5 Gy, fludarabine-total body irradiation combinations, or fludarabine-based conditioning. The MAC preparative regimens included mostly total body irradiation or busulfan-based combinations.

Definitions, Study Endpoints and Statistical Analysis {#S5}
-----------------------------------------------------

The primary objective was to compare overall survival (OS) after HCT between patients undergoing MUD, MMUD and UCB transplants, while adjusting for patient, disease, and transplant-related characteristics. Patient, disease and transplant-related factors were compared between groups using the Chi-square test for categorical variables and the Wilcoxon sample test for continuous variables. Surviving patients were censored at the time of last contact. Secondary endpoints were progression-free survival (PFS), relapse, non-relapse mortality (NRM), grade II-IV acute graft versus host disease (GvHD), and chronic GvHD.^[@R23],[@R24]^ Adjusted survival probabilities of OS and PFS for the 3 donor groups were estimated based on Cox proportional hazards models.^[@R25]^ Adjusted cumulative incidence rates were calculated for relapse and non-relapse mortality (NRM) to accommodate competing risks.^[@R26]^ Acute and chronic GVHD were defined calculated using cumulative incidence function. Multivariate analysis used Cox\'s proportional hazard model.^[@R27]^ All clinical variables were tested for proportional hazards assumptions. Factors violating the proportional hazards assumption were adjusted through stratification. We stratified models for OS, PFS, relapse and NRM based on same set of variables (i.e., Karnofsky performance score, lymphoma subset, GvHD prophylaxis, disease status). Stepwise model building procedures used a significance threshold of 0.05 for both entry and retention in the models. The main effect variable of donor type (MUD vs. MMUD vs. UCB) was forced into the models, and a random effect in the model was used to adjust for the center effect. Interactions between the main effect variable and adjusted covariates were tested at a significance level of 0.01. No significant interactions between the donor type variable and adjusted covariates were detected in any of the models. The results are reported at 3 years post-transplant.

RESULTS {#S6}
=======

Patients, Disease, and Transplant Characteristics {#S7}
-------------------------------------------------

We studied 1593 patients with NHL and HL treated at 119 centers. Baseline patient, disease, and transplant-related characteristics of UCB (n=142), MMUD (1 allele mismatched n=106; 1 antigen mismatched n=169) and MUD (n=1176) recipients are summarized in [Table 1](#T1){ref-type="table"}. The median age at transplant was 50 (MUD), 45 (MMUD) and 45 (UCB) years. The MUD cohort included more males, more often had mantle cell NHL and less often had HL. Both MUD and MMUD graft types were mostly peripheral blood male-male donor-recipient sex matched ([Table 1](#T1){ref-type="table"}). About half of recipients in three donor groups were cytomegalovirus sero-positive. More UCB recipients were non-Caucasian, had higher Karnofsky performance score, more had chemotherapy-sensitive disease and received prior radiation-therapy. Sixty-three percent (n=90) of UCB transplants used two UCB unit grafts. The median TNC dose of combined UCB units was 2.8 × 10e7/kg (range, 0.2-9.5) and were mostly HLA locus 5/6 (28%) or 4/6 (55%) matched. Notably, 45% (n=23) of single and 29% (n=26) of double UCB grafts were small providing \<2.5× 10e7 TNC/kg. UCB HCT had the shortest interval from diagnosis to transplant (median 27 months). In each donor group, about 70% received a RIC transplant. The proportion of patients with prior autograft, chemosensitive disease and type of conditioning in different lymphoma subsets were similar in each donor group. Recipients of MUD and MMUD were more likely to receive a tacrolimus based GvHD prophylaxis regimen and anti-thymocyte globulin (ATG) or alemtuzumab than UCB recipients. GvHD prophylaxis for UCB transplants more often included cyclosporine plus mycophenolate mofetil. Donor/recipient sex, donor/recipient cytomegalovirus status, and graft type (marrow vs blood) were similar in adult unrelated donors. The median follow-up of survivors in the MUD, MMUD and UCB groups was 57 months (range 6-129), 65 months (range 12-125) and 25 months (range 6-73; p\<0.001), respectively.

Neutrophil and platelet engraftment {#S8}
-----------------------------------

Neutrophil engraftment at day 28 and day 100 was significantly more frequent in MUD and MMUD recipients as compared to UCB ([Table 2](#T2){ref-type="table"}). Platelet recovery to ≥20 × 10^9^/L at day 100 was also significantly better in MUD and MMUD than UCB ([Table 2](#T2){ref-type="table"}). In MUD, MMUD and UCB groups, median time to neutrophil recovery was 13 (0-106), 16 (1-75) and 21 (0-66) days and median time to platelet recovery was 16 (0-394), 25 (1-49) and 45 (0-334) days, respectively.

Non relapse mortality {#S9}
---------------------

The adjusted cumulative incidences of NRM at 3 years were 35% (MUD 95%CI 32-38%), 44% (MMUD 95%CI 39-50%) and 37% (UCB 95%CI 28-46%) ([Table 3](#T3){ref-type="table"}; [Figure 1A](#F1){ref-type="fig"}). In multivariate analysis, the NRM risk was significantly higher in MMUD compared to MUD recipients, while there was no difference between MMUD vs. UCB and MUD vs. UCB groups ([Figure 1A](#F1){ref-type="fig"}; [Table 4](#T4){ref-type="table"}). UCB graft cell dose did not significantly impact the NRM risk (UCB NC \< 2.5×10e7 versus ≥2.5×10e7 HR 1.37; p=0.13). The most common non-relapse cause of death among MUD and MMUD patients was infections (n=16 and 16), followed by GvHD (n=14 and 13). Organ failure (n=15 and 13) and non-engraftment were infrequent (n=3 and 1). In the UCB group the most frequent causes of NRM were infection (n=15), organ failure (n=11), non-engraftment (n=11), GvHD (n=4), and lymphoproliferative disorder (n=4). Graft failure was managed by 2^nd^ (n=10) or 3^rd^ transplant (n=1); only 2 patients with graft failure survived, both UCB recipients following 2^nd^ HCT.

Graft versus host disease {#S10}
-------------------------

Grade II-IV aGvHD was more frequent in MMUD and MUD as compared to UCB recipients ([Table 2](#T2){ref-type="table"}). Grade III-IV occurred at similar rate ([Table 2](#T2){ref-type="table"}). The cumulative incidence of chronic GvHD at 3 year was 2-fold higher in MMUD and MUD cohorts as compared to UCB ([Table 2](#T2){ref-type="table"}). In multivariate analysis the risk of aGvHD was significantly lower in UCB recipients as compared to MUD and MMUD ([Table 4](#T4){ref-type="table"}). The risk of chronic GvHD was highly significantly decreased in UCB recipients ([Table 4](#T4){ref-type="table"}).

Relapse/Progression {#S11}
-------------------

The 3-year risk of relapse/progression was lower in MMUD transplants but was not different in recipients of MUD and UCB grafts ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}; [Figure 1B](#F1){ref-type="fig"}). Relapse was not influenced by single or double unit UCB grafts or by total UCB TNC dose infused (data not shown). Relapse was the most frequent cause of death in all 3 donor groups affecting 285 (39%) in MUD, 64 (32%) in MMUD and 22 (29%) in UCB recipients. Twenty-five patients received donor lymphocyte infusion (DLI) for relapse; 23 (MUD) and 2 (MMUD). Only eight MUD recipients survive between 16 and 96 months after DLI.

Survival {#S12}
--------

Adjusted PFS at 3 years was 33% (MUD 95%CI 30-36%), 30% (MMUD 95%CI 25-35%) and 31% (UCB 95%CI 23-39%) ([Table 3](#T3){ref-type="table"}, [Figure 1C](#F1){ref-type="fig"}) with the risk of treatment failure not significantly associated with graft source ([Table 4](#T4){ref-type="table"}). Due to higher NRM and lower relapse risks in the MMUD group, the OS in 3 groups were similar ([Table 4](#T4){ref-type="table"}). Adjusted OS at 3 years in the 3 groups was 43% (95%CI 40-46%) in MUD, 37% (95%CI 32-43%) in MMUD and 41% (95%CI 33-50%) in UCB recipients ([Figure 1D](#F1){ref-type="fig"}). In UCB group, overall mortality was not influenced by TNC dose (low vs high HR 1.24; p=0.42).

DISCUSSION {#S13}
==========

In this large registry-based study, we analyzed the differences in transplant risks and clinical benefits in adults with HL and NHL receiving transplants from alternative donors. Comparative data are increasingly needed by the patients and their physicians to guide the decision-making regarding hematopoietic transplant donor options. The main findings of our study were that 1) survival was similar for three donor types; 2) the risk of acute and, in particular chronic GvHD was significantly lower in recipients of UCB; 3) there was quicker hematopoietic recovery in recipients of MUD and MMUD as compared to UCB, yet without significant influence on NRM and 4) MMUD recipients had lower risk of relapse as compared to MUD; however, this benefit was offset by increased NRM. Overall, between 37-43% patients with relapsed or refractory lymphoma using alternative donors survived beyond 3 years and the graft source did not significantly influence PFS or OS. These promising results compare favorably even to HLA-matched sibling donor transplants, yet the heterogeneity in subjects and lymphoma histology likely contribute to modest differences.^[@R1],[@R4],[@R28],[@R29]^ It is important to recognize that our cohort of lymphoma patients undergoing allograft is heterogeneous and skewed with high proportion of patients who were chemorefractory (27%), had failed autologous HCT (50%) and radiation therapy (70%). Thus some patients were heavily pre-treated and these unrelated donor HCTs were delayed and used after other modalities failed to control their disease. Furthermore, the UCB HCT were more recent and follow-up was shorter. Because some critical prognostic variables such as disease status and lymphoma subtype violated the proportional hazard assumption in 3 donor groups, we controlled for them by stratified analysis to answer the donor source risk association; thus the analysis was not designed to address influence of disease and patient-related factors on outcomes. Some potentially important variables such as comorbidity index were not available in this cohort. Despite several adverse features and heterogeneity of this cohort, these encouraging results clearly suggest that allotransplantation offers potentially curative therapy which can be extended to almost all patients with high-risk lymphoma, even those without an available HLA matched sibling. Future studies investigating different lymphoma subsets are needed to refine our conclusions.

Importantly, our results highlight the acceptable transplant outcomes of MMUD and UCB HCT.^[@R9],[@R15],[@R28]^ In MMUD, the HLA-mismatch seems to have driven greater alloreactivity as evidenced by higher incidences of aGvHD and cGvHD and a lower risk of relapse. The benefit of lower relapse was offset by higher risk of NRM resulting to similar survival as compared to UCB and MUD. Future efforts to improve MMUD HCT need to focus on better patient selection and innovative strategies to reduce GvHD. Recent much larger registry studies demonstrated impairment of survival after single allele mismatch and adverse effect of HLA-C antigen mismatching, therefore we acknowledge that our results maybe impacted by smaller cohort size.^[@R30]-[@R32]^ Validation in larger study and cautious interpretation is therefore warranted.

We observed a lower risk of acute and chronic GvHD in UCB recipients as compared to MUD and MMUD, although in vivo T-cell depletion that can reduce the risk for acute GvHD was used frequently in MUD and MMUD. Lower risk of GvHD and greater HLA--mismatch in UCB HCT did not compromise the alloreactivity against lymphomas. As GvHD contributes to morbidity and mortality and can compromise the quality of life of long-term survivors, a lower risk of both acute and chronic GvHD after UCB HCT may be an additional favorable feature influencing donor choice. UCB transplant were used more frequently for ethnic minorities since suitable UCB units mismatched in 1 or 2 HLA loci can provide a graft for 90-95% of patients with minority backgrounds, who less often identify a MUD.^[@R33]^

These data demonstrate that successful allogeneic donor HCT can be available for all adult lymphoma patients including those of minority ethnic groups with rare HLA haplotypes. Our study supports prospective testing of UCB and MMUD in lymphoma such as randomized CTN trial comparing UCB to haploidentical donor. Our results mandate that patients with lymphoma in whom allograft is indicated have wider access to alternative donor options.
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###### 

\(A\) Non-Relapsed Mortality: Adjusted 3-year non-relapse mortality by donor groups

\(B\) Relapse: Adjusted 3 year relapse rate by donor groups.

\(C\) Progression-Free Survival: Adjusted 3 year progression-free survival by donor groups.

\(D\) Overall Survival: Adjusted 3 years overall survival by donor groups.
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###### 

Characteristics of patients that underwent allogeneic hematopoietic cell transplantation for NHL and HL reported to the CIBMTR between 2000 and 2010, by graft type.

  Characteristics of patients                                                       MUD          MMUD          UCB          P-value
  --------------------------------------------------------------------------------- ------------ ------------- ------------ ---------
  **Number of patients**                                                            **1176**     **275**       **142**      
  Age, median (range), years^[\*](#TFN1){ref-type="table-fn"}^                      50 (18-75)   45 (18-71)    45 (19-73)   \<0.001
  Male sex^[\*](#TFN1){ref-type="table-fn"}^                                        749 (64)     164 (60)      79 (56)      0.106
  Karnofsky performance score^[\*](#TFN1){ref-type="table-fn"}^                                                             0.097
      \<90%                                                                         349 (30)     98 (36)       37 (26)      
      ≥90%                                                                          709 (60)     152 (55)      96 (68)      
      Missing                                                                       118 (10)     25 ( 9)       9 ( 6)       
  Race^[\*](#TFN1){ref-type="table-fn"}^                                                                                    \<0.001
      Caucasian                                                                     1122 (95)    246 (89)      110 (77)     
      Black                                                                         21 ( 2)      16 ( 6)       18 (13)      
      Others^[\*\*](#TFN2){ref-type="table-fn"}^                                    33 ( 3)      13 ( 5)       14 (10)      
  Interval from diagnosis to transplant, months^[\*](#TFN1){ref-type="table-fn"}^   34 (3-312)   32 (3-247)    27 (2-203)   0.168
  Previous autologous transplant^[\*](#TFN1){ref-type="table-fn"}^                  485 (41)     134 (49)      64 (45)      0.067
  Interval from autoHCT to alloHCT, months^[\*](#TFN1){ref-type="table-fn"}^        20 (6-175)   19 (6-154)    18 (6-139)   0.894
  Histology^[\*](#TFN1){ref-type="table-fn"}^                                                                               0.074
      Hodgkin lymphoma                                                              233 (20)     74 (27)       39 (27)      
      Follicular/ other indolent lymphoma                                           294 (25)     59 (21)       30 (21)      
      DLBCL/other aggressive B cell lymphoma                                        282 (24)     70 (25)       39 (27)      
      Mantle cell lymphoma                                                          212 (18)     38 (14)       13 ( 9)      
      Mature T cell and NK cell neoplasm                                            155 (13)     34 (12)       21 (15)      
  Chemosensitive status prior to transplant^[\*](#TFN1){ref-type="table-fn"}^       818 (69)     183 (67)      107 (76)     0.201
  Disease status prior to transplant                                                                                        0.363
      First partial remission                                                       143 (12)     27 (10)       23 (16)      
      PIF resistant                                                                 128 (11)     34 (12)       13 ( 9)      
      CR1                                                                           72 ( 6)      13 ( 5)       15 (11)      
      Second partial remission                                                      315 (27)     77 (28)       34 (24)      
      REL resistant                                                                 230 (20)     58 (21)       22 (16)      
      CR2+                                                                          220 (18)     54 (20)       26 (18)      
      REL untreated/unknown                                                         26 ( 2)      7 ( 2)        2 ( 1)       
      Missing                                                                       42 ( 4)      5 ( 2)        7 ( 4)       
  Prior radiation therapy^[\*](#TFN1){ref-type="table-fn"}^                         751 (64)     194 (71)      116(82)      \<0.001
  Graft type^[\*](#TFN1){ref-type="table-fn"}^                                                                 NA           NA
      Bone marrow                                                                   259 (22)     74 (27)                    
      Peripheral blood                                                              913 (78)     201 (73)                   
  Recipient Cytomegalovirus serology^[\*](#TFN1){ref-type="table-fn"}^                                                      0.089
      Positive                                                                      622 (53)     136 (49)      79 (56)      
      Negative                                                                      552 (47)     138 (50)      61 (43)      
      Missing                                                                       2 (\<1)      1 (\<1)       2 ( 1)       
  One antigen/allele mismatch by locus                                              NA                         NA           NA
      HLA-A                                                                                      78 (28)                    
      HLA-B                                                                                      38 (14)                    
      HLA-C                                                                                      130 (47)                   
      HLA-DRB1                                                                                   29 (11)                    
  Donor-Recipient sex match                                                                                    NA           NA
      Male-Male                                                                     531 (45)     112 (41)                   
      Male-Female                                                                   277 (24)     58 (21)                    
      Female-Male                                                                   189 (16)     51 (19)                    
      Female-Female                                                                 132 (11)     53 (19)                    
  Year of transplant^[\*](#TFN1){ref-type="table-fn"}^                                                                      \<0.001
      2000-2003                                                                     338 (29)     97 (35)       21 (15)      
      2004-2006                                                                     463 (39)     134 (49)      34 (24)      
      2007-2010                                                                     375 (32)     44 (16)       87 (61)      
  Conditioning regimen^[\*](#TFN1){ref-type="table-fn"}^                                                                    \<0.001
      Myeloablative                                                                 302 (26)     81 (29)       41 (29)      
      Reduced intensity                                                             874 (74)     194 (71)      101 (71)     
  Total number chemotherapy lines, median                                           4 (1-5)      4 (1-5)       3 (1-5)      \<0.001
  ATG/alemtuzumab^[\*](#TFN1){ref-type="table-fn"}^                                                                         \<0.001
      ATG and alemtuzumab                                                           1 (\<1)      1 (\<1)       0            
      ATG alone                                                                     296 (25)     88 (32)       51 (36)      
      alemtuzumab alone                                                             138 (12)     38 (14)       1 ( 1)       
      No ATG or alemtuzumab                                                         740 (63)     148 (54)      89 (63)      
  Graft versus host disease prophylaxis^[\*](#TFN1){ref-type="table-fn"}^                                                   \<0.001
      Tacrolimus + others                                                           809 (69)     179 (65)      56 (39)      
      Cyclosporine + others                                                         177 (15)     43 (16)       65 (46)      
      Other^[\*\*\*](#TFN3){ref-type="table-fn"}^                                   28 ( 4)      4 ( 3)        7 ( 5)       
  Median follow-up of survivors (range), months                                     57 (6-129)   65 (12-125)   25 (6-73)    

[Abbreviations]{.ul}: UCB umbilical cord blood; MUD matched unrelated donor; MMUD mismatched unrelated donor; DLBCL diffuse large B cell lymphoma, TBI total body irradiation, ATG antithymocyte globulin

Variables tested in Cox proportional hazards regression models.

Other race includes: Asian/Pacific Islander n=18 (UCB=7, MUD=8, MMUD=3), Middle East or Northcoast of Africa n=2 (MUD=1, MMUD=1), Hispanic n=5 (MUD=3, MMUD=2) and others (UCB=7, MUD=21, MMUD=7).

Other graft versus host disease prophylaxis includes: ATG only=1, ATG/Methotrexate=1, Methotrexate only=1, Missing=26.

###### 

Outcomes after hematopoietic cell transplantation by donor type

  Outcomes                           MUD N=1173   MMUD N=274   UCB N=140    P-value
  ---------------------------------- ------------ ------------ ------------ ---------
  Neutrophil recovery                                                       
      at 28 days                     94 (92-95)   94 (90-96)   66 (57-73)   \<0.001
      at 100 days                    95 (94-96)   95 (92-97)   87 (80-92)   0.023
  Platelet recovery ^3^ 20 × 10^9^                                          
      at 100 days                    86 (84-88)   85 (80-89)   68 (59-76)   \<0.001
  Acute GvHD (II-IV)                                                        
      at 100 days                    37 (35-40)   49 (43-55)   26 (19-34)   \<0.001
  Acute GvHD (III-IV)                                                       
      at 100 days                    20 (18-22)   24 (19-29)   17 (11-23)   0.17
  Chronic GvHD                                                              
      at 3 years                     51 (48-54)   48 (42-54)   22 (15-30)   \<0.001

[Abbreviations:]{.ul} UCB umbilical cord blood, MMUD 1 Ag or 1 allele mismatched unrelated donor, MUD matched unrelated donor, GvHD graft versus host disease

###### 

Three-year adjusted probabilities.

  Outcomes                        MUD          MMUD         UCB          UCB vs MUD   UCB vs MMUD   MMUD vs MUD
  ------------------------------- ------------ ------------ ------------ ------------ ------------- -------------
  **Non relapse mortality**       35 (32-38)   44 (39-50)   37 (28-46)   0.63         0.19          0.004
  **Relapse**                     33 (30-36)   25 (20-30)   30 (22-38)   0.48         0.27          0.003
  **Progression-free survival**   33 (30-36)   30 (25-35)   31 (23-39)   0.72         0.81          0.35
  **Overall survival**            43 (40-46)   37 (32-43)   41 (33-50)   0.77         0.45          0.073

Abbreviations: UCB umbilical cord blood, MMUD mismatched unrelated donor, MUD matched unrelated donor, Adjusted probabilities of progression-free survival, overall survival, relapse and non-relapse mortality for the 3 donor groups were based on a stratified Cox regression model. Karnofsky performance score, lymphoma subset, Graft versus host disease prophylaxis and disease status violated the proportionality assumption, and therefore, all the models were stratified on these variables.

###### 

Multivariate analysis of factors associated with risk of NRM, acute GvHD, chronic GvHD, relapse, PFS and OS.

  Variable                                                         HR (95% Confidence interval)   P-value
  ---------------------------------------------------------------- ------------------------------ -------------------
  **Non relapse mortality^[a](#TFN4){ref-type="table-fn"}^**                                      
      MUD                                                          Ref                            P~overall~=0.08
      UCB                                                          1.22 (0.87-1.72)               0.24
      MMUD                                                         1.32 (1.03-1.69)               0.02
      MMUD vs. UCB                                                 1.07 (0.76-1.52)               0.68
  **Grade II-IV acute GvHD^[b](#TFN5){ref-type="table-fn"}^**                                     
      MUD                                                          Ref                            P~overall~\<0.001
      UCB                                                          0.68 (0.46-1.00)               0.050
      MMUD                                                         1.44 (1.18-1.75)               \<0.001
      MMUD vs UCB                                                  2.12 (1.52-2.95)               \<0.001
  **Chronic GvHD^[c](#TFN6){ref-type="table-fn"}^**                                               
      MUD                                                          Ref                            P~overall~\<0.001
      UCB                                                          0.35 (0.21-0.56)               \<0.001
      MMUD                                                         1.15 (0.90-1.48)               0.240
      MMUD vs UCB                                                  3.32 (1.99-5.54)               \<0.001
  **Relapse^[d](#TFN7){ref-type="table-fn"}^**                                                    
      MUD                                                          Ref                            P~overall~=0.11
      UCB                                                          1.08 (0.72-1.63)               0.70
      MMUD                                                         0.75 (0.58-0.98)               0.03
      MMUD vs UCB                                                  0.69 (0.42-1.14)               0.15
  **Progression-free survival^[e](#TFN8){ref-type="table-fn"}^**                                  
      MUD                                                          Ref                            P~overall~=0.24
      UCB                                                          1.22 (0.96-1.54)               0.09
      MMUD                                                         1.07 (0.88-1.29)               0.49
      MMUD vs UCB                                                  0.88 (0.67-1.13)               0.31
  **Overall Survival^[f](#TFN9){ref-type="table-fn"}^**                                           
      MUD                                                          Ref                            P~overall~=0.16
      UCB                                                          1.14 (0.89-1.47)               0.29
      MMUD                                                         1.19 (0.98-1.45)               0.08
      MMUD vs UCB                                                  1.04 (0.77-1.40)               0.77

[Abbreviations]{.ul}: HCT hematopoietic cell transplantation, UCB umbilical cord blood; MUD matched unrelated donor, MMUD 1 Ag or allele mismatched unrelated donor, GvHD graft versus host disease, ATG antithymocyte globulin, CsA cyclosporine, MAC myeloablative conditioning, RIC reduced intensity conditioning.

Other prognostic factors in the models

Age, time from diagnosis to HCT, race, conditioning regimen, prior auto HCT, & year of HCT

ATG/alemtuzumab use, GvHD prophylaxis, time from diagnosis to HCT, & disease status.

ATG/alemtuzumab use

ATG/alemtuzumab use

Year of HCT

Age, time from diagnosis to HCT, conditioning regimen, & year.

[^1]: C.B. and W.S. share senior authorship.
